Inflation Reduction Act

The Inflation Reduction Act (IRA) is poised to have significant implications for many pharma companies in the near future. Review the resources below for up-to-date information on how the IRA came to be, implications for the industry, and insights on recent updates.

Get In Touch

Marc Samuels shares his thoughts on predications for 2024 as they relate to the Inflation Reduction Act.
(January 12, 2024)

Listen Now

Marc Samuels Shares Insight on Important 2024 Regulatory Decisions with Pharma’s Almanac
(December 15, 2023)

Learn More

Sarah Butler shares some of the biggest challenges from 2023 as they relate to the Inflation Reduction Act.
(December 7, 2023)

Learn More

Lindsay Bealor Greenleaf shares that the IRA and government price controls were top focus areas in 2023.
(December 5, 2023)

Watch Now

Marc Samuels, ADVI CEO and president, discusses some of the biggest challenges from 2023 including the Inflation Reduction Act and its impact on oncology.
(December 4, 2023)

Listen Now

Listen in as ADVI expert Brenna Raines shares key takeaways from AVBCC Summit on the IRA.
(November 14, 2023)

Listen Now

Hear more from Caitlin Sheetz as she sheds light on key insights from a recent study and takeaways from AMCP Nexus.
(November 7, 2023)

Watch Now

Valuable insights in the complex and evolving landscape of the Inflation Reduction Act (IRA) from the 2023 Inovalon’s Customer Congress
(November 2, 2023)

Listen Now

IRA Update: ‘Bona Fide’ Marketing and the Latest on Government Negotiation
(August 9, 2023)

Watch Now

Vice president and head of policy, Lindsay Bealor Greenleaf, shared insights on the Inflation Reduction Act (IRA).

Hear more from Lindsay on what’s to come during the implementation of the IRA.

(September 15, 2023)

Listen Now

ADVI Expert Discusses Medicare Drug Pricing Negotiation’s “Spillover Effect” With AIS Health
(September 1, 2023)

Learn More

ADVI Expert Discusses Inflation Reduction Act with Pink Sheet
(August 31, 2023)

Learn More

On September 1, CMS will announce the first 10 drugs that will be targeted for government negotiation under the IRA.

ADVI has early insights on which drugs made the list.

(August 1, 2023)

Read More

Having an approved and marketed generic or biosimilar does not necessarily exclude the innovator drug from the IRA government negotiation policy.

(July 25, 2023)

Read More

The CMS will only consider active designations for the IRA Orphan Drug Exclusion. 

(July 18, 2023)

Learn More

ADVI Instant: IRA Update – CMS Issues Revised Negotiation Guidance

(June 30, 2023)

Learn More

ADVI Health Expert Discusses CMS’ Inflation Rebate Guidance With AIS Health
(Feb 23, 2023)

Read Article

At the 2023 Biopharma Congress, our ADVI experts examined this new wave of changes following the IRA.

Here are key takeaways that came out of the compelling discussion.

(February 23, 2023)

Learn More

ADVI Experts Lindsay Bealor Greenleaf and Brenna Raines discuss prescription drug pricing following the Inflation Reduction Act.
(January 23, 2023)

Watch Now

AVBCC 2022 Key Takeaways: The impact of the IRA is beyond impacts to pricing
(Oct 26, 2022)

Read Article

ADVI Leaders Share IRA Insights with Managed Healthcare Executive

(Oct 13, 2022)

Read Article

ADVI Expert Speaks With Modern Healthcare About What the IRA Means for PBMs (Oct 18, 2022)

Read Article

ADVI Instant: Congress just passed the Inflation Reduction Act
(Aug 12, 2022)

Read Article

Given the potential loss of countless new lifesaving treatments and of the ability to live longer, healthier lives, the gravity of the Inflation Reductin Act cannot be overstated.

Lindsay Bealor Greenleaf, Vice President and Head of Policy and Reimbursement

Seize The Opportunity

image description

Schedule a consultation on your current challenge.

Leverage our Expertise
image description

Submit an RFP and let’s determine how our team of experts can support your business.

Submit an RFP
image description

Get our incisive analysis delivered straight to your inbox.

Keep Me Informed

Policy and Reimbursement